3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
26
Pancreatic Neoplasms
11
Stomach Neoplasms
10
Rectal Neoplasms
10
Colonic Neoplasms
10
Esophageal Neoplasms
8
Adenocarcinoma Of Esophagus
8
Neoplasm Metastasis
6
Urinary Bladder Neoplasms
5
Neoplasms
5
Cholangiocarcinoma
5
Carcinoma, Non-Small-Cell Lung
5
Adenocarcinoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Squamous Cell Carcinoma of Head and Neck
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Carcinoma, Hepatocellular
3
Ovarian Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Carcinoma
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Carcinoma of the Bladder
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
testosterone 17 beta-cypionate
1
pembrolizumab
1
enfortumab vedotin
1
Testosterone Propionate
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Mitomycin
1
Methyltestosterone
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Diseases
×
Fluorouracil
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled